Sangamo Therapeutics ( NASDAQ:SGMO ) First Quarter 2024 Results Key Financial Results Revenue: US$481.0k (down 100...
Assessing Sangamo's Financial Health and Strategic Progress Amidst Challenges
Sangamo (SGMO) delivered earnings and revenue surprises of -22.73% and 94.35%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?